Nanotherapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Nanotherapeutics's estimated annual revenue is currently $4.8M per year.
- Nanotherapeutics's estimated revenue per employee is $201,000
Employee Data
- Nanotherapeutics has 24 Employees.
- Nanotherapeutics grew their employee count by -20% last year.
Nanotherapeutics's People
Name | Title | Email/Phone |
---|
Nanotherapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $26.5M | 132 | N/A | N/A | N/A |
#2 | $10.1M | 50 | 14% | N/A | N/A |
#3 | $282.6M | 1406 | N/A | N/A | N/A |
#4 | $13.9M | 69 | 44% | N/A | N/A |
#5 | $11.3M | 56 | 4% | N/A | N/A |
#6 | $11.5M | 57 | -7% | N/A | N/A |
#7 | $211.7M | 1072 | 4% | N/A | N/A |
#8 | $24.1M | 120 | 5% | N/A | N/A |
#9 | $7.8M | 39 | -2% | N/A | N/A |
#10 | $12.9M | 64 | -2% | N/A | N/A |
What Is Nanotherapeutics?
Nanotherapeutics is a privately-held emerging biopharmaceutical company with both proprietary platform technologies and a diversified pipeline of products. The Company has expertise in pre-clinical and clinical development, formulation optimization, and cGMP manufacturing of biopharmaceutical products and medical devices. The Company's proprietary platform technologies can be used with all drug types, ranging from small molecules to proteins and vaccines. Many of our diversified products have multiple indications ("dual-use") with potential in the areas of infectious diseases, CNS, oncology, vaccines, and biodefense. Over the past several years, we have focused our efforts on meeting the US government's interests to develop safe, effective medical countermeasures against certain biological and radiological threats.
keywords:N/AN/A
Total Funding
24
Number of Employees
$4.8M
Revenue (est)
-20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Nanotherapeutics News
Amgen; Celgene; MagForce AG; Nanotherapeutics; Spectrum Pharmaceuticals; Ablynx(Sanofi); AMAG; CytImmune; Delpor; Nanospectra; Merrimack; Tarveda.
Amgen, Celgene, MagForce AG, Nanotherapeutics, Spectrum Pharmaceuticals, Ablynx, AMAG, CytImmune, Delpor, Nanospectra, Merrimack, Tarveda.
Nanotherapeutics have shed new light onto HCC treatment by enabling site-specific in vivo delivery of chemotherapeutics specifically to...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 26 | -10% | N/A |
#2 | $3.5M | 30 | -6% | N/A |
#3 | $4.8M | 31 | -56% | N/A |
#4 | $4.8M | 31 | -56% | N/A |
#5 | $5M | 32 | 10% | N/A |